Not good for some hedge funds: "80 hedge funds counted Allergan as one of their top 10 holdings at the end of the fourth quarter"
Not good for senior execs either of course, nor for the advising banks due to lose out on $100 million of fees (Goldman, Guggenheim, Centerview, Moelis & Company), and JPMorgan and Morgan Stanley lose out on dozens of millions of investment banking fees.
Maybe good for some of the workers, who won't lose their job to "synergies" anymore?